A year on, China is shaking up the world"Our first phase (of vaccination) comprises priority groups with high risk of mortality and our healthcare and frontline workers.
For them, we believe, we have enough (COVID-19 vaccine) stockpile," he told PTI in an interview.India's drug regulator DCGI on Sunday approved the Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation drive.Paul noted that "three to four months from now, there will be other vaccines and the stockpile will be even bigger.